Olema Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
13/05/2025 21:32
Olema Pharmaceuticals Inc OLMA.OQ reported a quarterly adjusted loss of 36 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -56 cents. The mean expectation of four analysts for the quarter was for a loss of 51 cents per share. Wall Street expected results to range from -59 cents to -39 cents per share. Reported revenue was zero; analysts expected zero. Olema Pharmaceuticals Inc's reported EPS for the quarter was a loss of 36 cents. The company reported a quarterly loss of $30.39 million. Olema Pharmaceuticals Inc shares had risen by 26.6% this quarter and lost 18.4% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 19.5% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Olema Pharmaceuticals Inc is $27.00 This summary was machine generated from LSEG data May 13 at 08:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.51 | -0.36 | Beat |
| Dec. 31 2024 | -0.64 | -0.51 | Beat |
| Sep. 30 2024 | -0.58 | -0.60 | Missed |
| Jun. 30 2024 | -0.55 | -0.54 | Beat |
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs